Year: 2022

TORONTO, Oct. 04, 2022 (GLOBE NEWSWIRE) — Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the “Company” or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at Cantor Fitzgerald’s “Symposium on Mental Health Clinics,” taking place on Tuesday, October 11, 2022. Mujeeb Jafferi, President of Field Trip, will present at the virtual fireside chat at 8:00 a.m. Eastern Time on Tuesday, October 11, 2022. To view the fireside chat, please register through the following link: https://us06web.zoom.us/webinar/register/WN_H5A2A4j4Sd2N8-3VHfRfPw. The webcast recording will also be accessible on Field Trip’s investor relations website. Institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic...

LANGHORNE, Pa., Oct. 04, 2022 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that Adam Levy, CEO, will participate at the Dawson James Securities 7th Annual Small Cap Growth Conference in Jupiter, Florida and the LD Micro Main Event XV Conference in Los Angeles, California in October 2022. Dawson James Securities 7thAnnual Small Cap Growth Conference Date: Wednesday, October 12th, 2022Time: Wednesday, October 12th at 5:00 P.M. ETLocation: Wyndham Grand Hotel at Jupiter, FloridaTo attend, please contact your Dawson James representative. LD Micro Main Event XV Date: Tuesday, October 25th – Wednesday, October 27th, 2022Time: Wednesday, October 26th at 8:30 A.M. PT Location:...

Harpoon adds experienced drug developer to leadership team SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead the clinical development strategy and its execution for Harpoon Therapeutics and the product candidates derived from the company’s multiple technology platforms. Dr. Walker will report to Julie Eastland, Harpoon Therapeutics’ President and Chief Executive Officer, and his appointment was effective October 3, 2022. “I’m excited to join Harpoon Therapeutics and work alongside science-driven, collaborative colleagues, who are driven by the potential to impact patients’ lives by developing novel therapeutics,”...

Topline VIITAL™ study results expected within the next month NEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic epidermolysis bullosa (RDEB). “Completion of the last patient’s 6-month follow-up visit marks a key milestone that enables us to report key findings from our Phase 3 VIITAL™ study of EB-101 in RDEB,” said Vish Seshadri, Chief Executive Officer of Abeona. “We thank the patients, their families, and the clinical investigators, and plan to report topline results from this pivotal study within the next month.” Abeona has been verifying and preparing the...

CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) — KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, announced its support for Niemann-Pick Awareness Month, which is the month of October, and Global Niemann-Pick Awareness Day, which is October 19th. KemPharm recognizes the important role and dedication of patient organizations, such as the National Niemann Pick Disease Foundation (NNPDF), and the International Niemann Pick Disease Alliance (INPDA), in not only raising awareness of Niemann-Pick disease type C (NPC), but also in providing advice, information and education to those living with NPC, their families, other caregivers, and all involved in the management of this disease. KemPharm supports...

Blue Arc EV and Power Cube In the drive to electrify commercial vehicle fleets, Blue Arc™ EV Solutions brings a unique edge to the competition: nearly 50 years of experience in custom chassis and work truck body design and manufacturing as part of The Shyft Group.Investors, customers, dealers and government officials sign up to drive theBlue Arc Class 3 Electric Delivery Vehicle Company selects Tier 1 mobility suppliers for key vehicle systems Management to provide analyst and investor update at 4:15PM ET NOVI, Mich., Oct. 04, 2022 (GLOBE NEWSWIRE) —  In the drive to electrify commercial vehicle fleets, Blue Arc™ EV Solutions brings a unique edge to the competition: nearly 50 years of experience in custom chassis and work truck body design and manufacturing as part of The Shyft Group (NASDAQ: SHYF). Poised to lead as the only...

New Program Designed to Support Provider Partners with Onsite Coordinator LEXINGTON, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today launched its new Marketplace Onsite program to offer additional support to the Company’s biospecimen provider partners. The program embeds a coordinator at select partner sites to facilitate fulfillment of incoming sample and data requests from the proprietary iSpecimen Marketplace® platform. With this extra layer of support, iSpecimen and its partners will be able to expand and streamline access to biospecimens for research. The Marketplace Onsite coordinator will field all requests and submit...

In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococcus neoformans These data suggest Brilacidin has potential as a novel antifungal agentWAKEFIELD, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of a scientific article on the antifungal activity of Brilacidin, the Company’s defensin-mimetic drug candidate with antimicrobial and immunomodulatory properties. The paper, accessible at the link below as a preprint and to be submitted for peer review, is based on independent research conducted primarily by scientists...

HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally. Details regarding Bellicum’s presentation at the conference are as follows: Event: 2022 Cell & Gene Meeting on the Mesa Date: October 11, 2022Time: 4:30 p.m. PT Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011 Virtual attendance is available which includes a livestream of Bellicum’s presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemesa.com for full information including registration. Complimentary...

Figure 1 MD-SOQUEM Alliance in the Labrador TroughFigure 2 New Copper-Gold Discovery in Nachicapau AreaFigure 3 Nachicapau-Malachite & Bornite DiscoveryFigure 4 Nachicapau 2022 Rock Sampling WorkFigure 5 Nachicapau 2022 Rock Sampling WorkFigure 6 Nachicapau 2022 Channel SamplingFigure 7 Nachicapau 2022 Rock Sampling WorkMONTREAL, Oct. 04, 2022 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with SOQUEM Inc. (“SOQUEM”), is pleased to announce the discovery of several new metric to plurimetric mineralized horizons with high-grade copper and gold. This discovery is a result of the Strategic Alliance between Midland and SOQUEM (the “Alliance”) in the Labrador Trough in Nunavik, Quebec. During a prospecting campaign carried out in the summer of 2022, the Midland-SOQUEM...